Rick Soltero

Rick Soltero is the founder of PharmaDirections, a biotech company focused on chemically modifying proteins and peptides to make them orally available. Prior to founding PharmaDirections, Soltero served as the executive director of pharmaceutical and analytical development at Nobex Corporation from August 2000 to March 2003. While at Nobex, Soltero led the strategy and management of the company's lead product, oral insulin, which resulted in a $283 million licensing deal with GlaxoSmithKline (GSK).

Soltero also served as the vice president of laboratory operations at Magellan Laboratories from January 1997 to December 2000. In this role, they were responsible for managing multi-million dollar laboratory businesses including analytical chemistry, method development and microbiology. Rick was also responsible for implementing a laboratory information management system for Pharmacopeia testing.

Before joining Magellan Laboratories, Soltero served as the vice president of laboratory operations at AAI from January 1995 to December 1997.

Rick Soltero has a Ph.D. in Physical Chemistry from Rutgers University - Newark, an M.S. in Chemistry from Rutgers University - Newark, and a B.S. in Chemistry from Ramapo College of New Jersey.

Some individuals on their team include Bruce Rehlaender - Principal, Murali Duvvuri - Principal, and Cathi Clark - VP of Business Development & Operations.